Silence Therapeutics News and Activities

Silence Therapeutics is a company listed under the stock ticker SLN (GB).

View the org chart displaying its 25 main executives

Most searched biographies at Silence Therapeutics

• Ian Ross, Chairman of the Board and Interim Chief Executive Officer
• Dave Lemus, Non-Executive Director
• James Ede-Golightly, Non-Executive Director

Popular executive movements at Silence Therapeutics

• Ian Ross, who was Non-Executive Chairman of the Board, is promoted to Chairman of the Board and Interim Chief Executive Officer  (posted on December 15 2025).
• Craig Tooman, President and Chief Executive Officer, has left the company  (posted on December 15 2025).

Create your alert
to follow the executive moves at Silence Therapeutics.

Silence Therapeutics has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Silence Therapeutics

• Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
• Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
• Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
• Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
• Endpoints at #ASH25
• Silence Therapeutics Announces Leadership Changes
• Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
• Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
• Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
• Silence Therapeutics to Participate in September Investor Conferences
• View more press releases Close

Social media about Silence Therapeutics

• Silence Therapeutics on Wikipedia, Google News & Yahoo Finance
• Silence Therapeutics on LinkedIn, X (Twitter) & YouTube